Drug Trial Radar · NCT06401356
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 13, 2024
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients with hematological malignancies) or only the Survival Follow-up (for all the other patients).
Conditions
- Hematologic Malignancy
- Solid Tumor
- Advanced Malignancies
Interventions
PelabresibDrug
Small molecule inhibitor of bromodomain and extraterminal (BET) protein
RuxolitinibDrug
Small molecule selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs) and serious TEAEsTime frame: 5 years
- Survival Follow-upTime frame: 5 years
- Duration of Response (DoR)Time frame: 5 years
- Progression-free survival (PFS)Time frame: 5 years
- Leukemia-free survival (LFS)Time frame: 5 years
Locations
15 sites in 5 countries. Site status is shown where the registry gives one.
University of California LA
Los Angeles, California · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Uni Of Michigan Health System
Ann Arbor, Michigan · Recruiting
New York Presbyterian Hospital
New York, New York · Recruiting
Mt Sinai Medical Center
New York, New York · Recruiting
Novartis Investigative Site
Antwerp, Belgium · Recruiting
Novartis Investigative Site
Bruges, Belgium · Recruiting
Novartis Investigative Site
Novara, Italy · Recruiting
Novartis Investigative Site
Florence, FI, Italy · Recruiting
Novartis Investigative Site
Varese, VA, Italy · Recruiting
Novartis Investigative Site
Amsterdam, Netherlands · Recruiting
Novartis Investigative Site
Cardiff, United Kingdom · Recruiting
Novartis Investigative Site
Glasgow, United Kingdom · Recruiting
Novartis Investigative Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.